I am an Associate Professor in the School of Medicine (tenured September 2005, promoted August 2011). I joined the University of Nottingham Children's Brain Tumour Research Centre (CBTRC) in 2002 as an independent Research Fellow, based in the School of Biology. Previously, I was a research associate (1999-2002) with Professor Gerald Cohen in the Biochemical Toxicology Section of the MRC Toxicology Unit at the University of Leicester. My first postdoctoral position (1995-1999) was with Professor Richard Trembath in the Institute of Genetics at the University of Leicester. I obtained my my PhD at the MRC Human Genetics Unit ((University of Edinburgh; supervised by Professor David Porteous) in Edinburgh in 1995 and my BSc in Molecular Biology, also from the University of Edinburgh, in 1991 .
My research has always been dominated by an interest in investigating the genetics of childhood. I started my research career carrying out linkage analysis in patient samples from two different deafness disorders (Usher's Syndrome then Pendred Syndrome), finding the gene for Pendred Syndrome (Coyle et al. 1996 Nature Genetics 12:421-3) and mapping mutations in patient samples (another 6 papers in this area). At the MRC Toxicology Unit I applied my genetics skills to understanding apoptotic pathways in leukaemic and liver cancer cells (Coyle et al. 2003 JBC 278:5920-8). Since arriving at the Children's Brain Tumour Research Centre as an independent fellow, I have focused the work of my group on developing accurate tumour models in order to circumvent drug resistance and invasion/ metastasis in ependymomas and medulloblastomas. Over the past 14 years, I have brought in ~£900K of funding, mainly as a Co-I, and published another 24 papers in this area, playing a key role is several large international collaborations.
I lecture MSc students on the Stem Cell Technology Course and BMedSci undergraduates on the role of stem cells in cancer. I lecture MSc students on the Translational Neuroscience module on… read more
My research is mainly focused on primitive neuroectodermal tumours (PNETs) and ependymomas both of which are inherently drug resistant. I am specifically interested in the role that cancer stem cells… read more
AL-GHAFARI, A. B., PUNJARUK, W., STORER, L. C. D., CARRIER, D. J., HUSSEIN, D., COYLE, B. and KERR, I. D., 2016. Long-term exposure to irinotecan reduces cell migration in glioma cells JOURNAL OF NEURO-ONCOLOGY. 127(3), 455-462 COYLE, BETH, KESSLER, MAYA, SABNIS, DURGAGAURI H. and KERR, IAN D., 2015. ABCB1 in children's brain tumours BIOCHEMICAL SOCIETY TRANSACTIONS. 43, 1018-1022 OTHMAN RT, KIMISHI I, BRADSHAW TD, STORER LCD, KORSHUNOV A, PFISTER SM, GRUNDY RG, KERR ID and COYLE B, 2014. Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta neuropathologica communications. 2, 57
ROGERS, HAZEL A., MAYNE, CERYS, CHAPMAN, REBECCA J., KILDAY, JOHN-PAUL, COYLE, BETH and GRUNDY, RICHARD G., 2013. PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival CLINICAL CANCER RESEARCH. 19(23), 6450-6460
I lecture MSc students on the Stem Cell Technology Course and BMedSci undergraduates on the role of stem cells in cancer. I lecture MSc students on the Translational Neuroscience module on pre-clinical cancer models. I lecture MSc students on the Clinical Neuroscience on brain tumours.
In the lab I supervise BSc and BMedSci undergraduates. I also take MSc students on the MSc Oncology and MSc Molecular Diagnostic courses.
I am currently the primary supervisor for 2 PhD students (Aishah Nasir and Durgagauri Sabnis ) and second supervisor for another 2 PhD students ( Musah-Eroje Ahmed and Shubaash Anthiya). I am advisor to another 6 PhD students from other schools and I have several medical student tutees.
My research is mainly focused on primitive neuroectodermal tumours (PNETs) and ependymomas both of which are inherently drug resistant. I am specifically interested in the role that cancer stem cells play in drug resistance. Currently, I am investigating ways to circumvent drug resistance mediated by MGMT, the BCl-2 family and multidrug transporters.
Before joining the CBTRC I worked at the MRC Toxicology unit in Leicester, investigating the transcriptional response to apoptotic inducing agents.The most informative system proved to be transforming growth factor-beta1 (TGFβ1)-induced apoptosis in FaO hepatoma. Although TGFβ1 acts via the SMAD signaling pathway to initiate de novo gene transcription, little was known about the downstream gene targets that are involved in the regulation of apoptosis. By data mining and cluster analysis of expression data I was able to identify an early response set of nine down-regulated genes that are involved in antioxidant defence that may in fact represent the primary mechanism through which TGFβ1 initiates apoptosis.
Prior to that I started my postdoctoral career in the Department of Genetics at the University of Leicester. I investigated the genetic basis of Pendred Syndrome, an autosomal recessive disorder associated with developmental abnormalities of the cochlea, sensorineural hearing loss, and diffuse thyroid enlargement. Using linkage analysis I identified the pendrin gene then 78% of the underlying mutations in 31 affected families. My PhD at the MRC Human Genetics Unit in Edinburgh was also focused on mapping and mutational analysis of another deafness disorder (Usher Syndrome Type IB).
I have recently become interested in investigating metastatic tumours, particularly from the perspective of whether or not these represent a different biological entity to the primary tumour. I would like to compare the response to therapy of primary to metastatic tumours in model systems.